Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly to Phase 3 clinical development.

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early next year. The Danish pharma and obesity heavyweight is moving forward ...

About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years.

Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025 ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership and board of directors. Per the press release, Lars Fruergaard ...

Novo Nordisk is managing the unusual feat of seeing its stock price rise after reducing its earnings outlook.

Asda customers have recycled over 3 million coffee pods this year after the supermarket launched a new coffee pod recycling service.

Lucknow: To promote maternal and child health, KGMU has established three baby feeding pods on its campus as part of corporate social responsibility (.

After testing the Eight Sleep's latest, here’s I think you should just stick with the Pod 3 and save $354.

Novo Nordisk has announced headline results from a late-stage study of its obesity candidate CagriSema in adults with type 2 diabetes (T2D). The phase 3 REDEFINE 2 trial has been evaluating ...